Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
Sponsor: Dongnam Institute of Radiological & Medical Sciences
This PHASE2 trial investigates Hepatocellular Carcinoma and is currently ongoing. Dongnam Institute of Radiological & Medical Sciences leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Oct 2021 — Feb 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2019 — Oct 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dongnam Institute of Radiological & Medical Sciences
- Incheon St.Mary's Hospital
- Inha University Hospital
- Inje University
- Korea Cancer Center Hospital
- Soonchunhyang University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .